Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAVE8062: a new combretastatin derivative vascular disrupting agent
Expert Opinion on Investigational Drugs, 10/06/09
Delmonte A et al. – VDAs specifically target and destroy well–established tumor vessels with ischemia and destruction of large masses with central hemorrhagic necrosis and survival of a thin peripheral tumor layer. VDAs can be divided into biologics, such as ligand–based, and small–molecule agents; this second group includes small–molecule VDAs like flavonoids, such as 5,6–dimethylxanthenone–4–acetic acid (DMXAA), and microtubule–destabilizing agents.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Sponsor
Article Search
Sponsor